【Helius Medical Technologies-Product PoNS】Helius Announces Authorization from Health Canada to Market the PoNS? Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)

Partner News

24th March, 2020 – Helius Medical Technologies issued an announcement, which is summarized as follows: 

Helius today announced that its Canadian Class II license amendment application for the treatment of gait deficit in patients with mild and moderate symptoms from multiple sclerosis (“MS”) has received marketing authorization from Health Canada. Helius’ Portable Neuromodulation Stimulator (PoNS?) device is now authorized to be marketed for the short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy, in addition to the short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy.

“We are very pleased to receive regulatory clearance to market our PoNS Treatment to the approximately 93,500 patients in Canada who suffer from MS,” said Philippe Deschamps, Chief Executive Officer of Helius. “Given the chronic and progressive nature of this potentially debilitating neurodegenerative disease, we feel that there is a strong clinical need for novel therapies such as our PoNS Treatment. We are proud to provide MS patients with a treatment option that has the potential to improve or restore their gait function, or in other words their ability to walk.”

Original website Link: